AbCellera (NASDAQ: ABCL) appoints oncology leader Dr. Victor Sandor as independent director
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
AbCellera Biologics Inc. announced that its Board of Directors appointed Dr. Victor Sandor as a new independent director. He will serve until the next annual meeting of shareholders and until a successor is elected and qualified, or earlier resignation or removal.
The Board determined that Dr. Sandor is independent under Nasdaq rules and the company’s Corporate Governance Guidelines. He will participate in AbCellera’s Non-Employee Director Compensation Policy on the same terms as other non-employee directors and currently has not been appointed to any Board committees.
AbCellera highlighted Dr. Sandor’s extensive oncology drug development background, including leadership roles at Array BioPharma, Incyte, Biogen, and AstraZeneca, where he contributed to multiple cancer therapy approvals. The company describes itself as a clinical-stage biotechnology firm focused on first-in-class antibody-based medicines across several therapeutic areas.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Terms
independent director, Non-Employee Director Compensation Policy, Definitive Proxy on Schedule 14A, Item 404(a) of Regulation S-K, +1 more
5 terms
independent director financial
"announced the appointment of Victor Sandor, M.D.C.M, to its Board of Directors as an independent director"
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
Non-Employee Director Compensation Policy financial
"he will participate in the Company's Non-Employee Director Compensation Policy on the same terms as the Company’s other non-employee directors"
Definitive Proxy on Schedule 14A regulatory
"as previously disclosed in the Company's Definitive Proxy on Schedule 14A filed with the Securities and Exchange Commission"
Item 404(a) of Regulation S-K regulatory
"Dr. Sandor has no direct or indirect material interest in any transaction pursuant to Item 404(a) of Regulation S-K"
clinical-stage biotechnology company financial
"AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines"
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________
FORM 8-K
__________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 1, 2026
__________________________________________
(Exact name of registrant as specified in its charter)
__________________________________________
| Not Applicable | ||||||||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) | ||||||
150 W 4th Avenue | |||||
| (Address of registrant’s principal executive office) | (Zip code) | ||||
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
__________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Director
On June 1, 2026, the Board of Directors (the "Board") of AbCellera Biologics Inc. (the "Company") appointed Victor Sandor as a new director. Dr. Sandor will serve until the Company’s next annual meeting of shareholders and until his successor is duly elected and qualified, or until his earlier resignation or removal.
The Board has affirmatively determined that Dr. Sandor is independent under the rules of The NASDAQ Stock Market LLC and the Company’s Corporate Governance Guidelines. Dr. Sandor has not been appointed to serve on committees of the Board.
In connection with Dr. Sandor’s service as a director, he will participate in the Company's Non-Employee Director Compensation Policy on the same terms as the Company’s other non-employee directors, as previously disclosed in the Company's Definitive Proxy on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2026.
Dr. Sandor has no direct or indirect material interest in any transaction pursuant to Item 404(a) of Regulation S-K. There are no arrangements or understandings between Dr. Sandor and any other person pursuant to which Dr. Sandor was appointed as a member of the Board.
A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press Release issued by AbCellera Biologics Inc. on June 5, 2026. | |||||||
| 104 | Cover Page Interactive Data File (embedded as Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: June 5, 2026 | ABCELLERA BIOLOGICS INC. | |||||||
| By: | /s/ Carl L. G. Hansen | |||||||
| Carl L. G. Hansen, Ph.D. | ||||||||
Chief Executive Officer and Director (Principal Executive Officer) | ||||||||
150 W 4th Ave Vancouver, BC V5Y 1G6 T 1. 604.559.9005 abcellera.com NEWS RELEASE AbCellera Appoints Dr. Victor Sandor to its Board of Directors 2026-06-05 VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced the appointment of Victor Sandor, M.D.C.M, to its Board of Directors as an independent director. “Dr. Sandor is an experienced director and a distinguished medical oncologist with experience in building companies and bringing innovative medicines to patients in need,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “I am pleased to welcome Dr. Sandor to AbCellera’s Board of Directors and look forward to working with him.” Before its acquisition by P�zer Inc., Dr. Sandor served as Chief Medical O�cer at Array BioPharma Inc. where he successfully secured approval of Braftovi® (encorafenib) and Mektovi® (binimetinib). Prior to joining Array, Dr. Sandor served as Senior Vice President for Global Clinical Development at Incyte Corporation, where he played a critical role in the approval of Jaka�® (ruxolitinib). Dr. Sandor was also Vice President and Chief Medical O�cer for Oncology at Biogen Inc. and held positions of increasing responsibility in oncology product development at AstraZeneca Pharmaceuticals LP, contributing to the registration of Arimidex® (anastrozole) and the development of Faslodex® (fulvestrant). "I am excited to join the AbCellera board at this important moment in the company's evolution. AbCellera has established an exceptional capability in antibody discovery, and I look forward to working with Carl and the team as the company advances its pipeline and translates that capability into meaningful clinical outcomes for patients,” 1
said Dr. Sandor. Dr. Sandor currently serves on the board of directors at ADC Therapeutics SA, Kymera Therapeutics Inc., and Prelude Therapeutics Incorporated. He also served on the board of Merus N.V. prior to its acquisition by Genmab A/S in 2025. Dr. Sandor received his M.D.C.M. from McGill University in Montreal, Canada, and completed a Fellowship in Medical Oncology at the National Institutes of Health in Bethesda, Maryland. About AbCellera Biologics Inc. AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing �rst- in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more. For more information, please visit www.abcellera.com. Inquiries Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774 Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005 Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116 Source: AbCellera Biologics Inc. 2
FAQ
What did AbCellera Biologics Inc. (ABCL) announce in this 8-K filing?
AbCellera reported that its Board appointed Dr. Victor Sandor as a new independent director. He will serve until the next annual shareholder meeting and participate in the company’s Non-Employee Director Compensation Policy like other non-employee directors, with no special appointment arrangements disclosed.
Who is Dr. Victor Sandor, the new AbCellera (ABCL) board member?
Dr. Victor Sandor is a medical oncologist and experienced biopharmaceutical executive. He previously served as Chief Medical Officer at Array BioPharma and held senior clinical development roles at Incyte, Biogen, and AstraZeneca, contributing to approvals of several oncology medicines over his career.
Is Dr. Victor Sandor considered independent under Nasdaq rules for AbCellera (ABCL)?
Yes, AbCellera’s Board affirmatively determined that Dr. Sandor is independent under the rules of The Nasdaq Stock Market and the company’s Corporate Governance Guidelines. This means he meets the prescribed standards for independence from management and significant business relationships.
Will Dr. Victor Sandor serve on any AbCellera (ABCL) board committees?
AbCellera stated that Dr. Sandor has not been appointed to serve on any Board committees at this time. His role is as a member of the Board of Directors, with potential future committee assignments not addressed in this disclosure.
How will AbCellera (ABCL) compensate Dr. Victor Sandor as a director?
Dr. Sandor will participate in AbCellera’s Non-Employee Director Compensation Policy on the same terms as other non-employee directors. The policy’s details were previously disclosed in the company’s Definitive Proxy Statement on Schedule 14A filed on April 29, 2026.